dcn-1 Antibody
Description
Introduction to DCUN1D1 (DCN1)
DCUN1D1, also termed DCN1, is a scaffold-type E3 ligase critical for neddylation—a post-translational modification essential for CRL activation . It facilitates the transfer of NEDD8 from the E2 enzyme UBC12 to cullins, enabling substrate ubiquitination and proteasomal degradation . Dysregulation of DCUN1D1 is implicated in cancers, including non-small cell lung carcinoma (NSCLC) and gliomas, where it promotes metastasis and invasiveness .
DCN1 Antibody Characteristics
The DCUN1D1 antibody (10965-1-AP) from Proteintech is a rabbit polyclonal IgG validated for multiple applications:
Recommended Dilutions
| Application | Dilution Range |
|---|---|
| WB | 1:2,000 – 1:12,000 |
| IHC | 1:50 – 1:500 |
Western Blot (WB)
Immunohistochemistry (IHC)
-
Localizes DCUN1D1 in human glioma tissues with antigen retrieval (TE buffer pH 9.0 or citrate buffer pH 6.0) .
Functional Studies
-
Validated in knockdown/knockout (KD/KO) models to study DCUN1D1’s role in cancer metastasis and CRL regulation .
Role in Cancer
-
DCUN1D1 overexpression in NSCLC correlates with brain metastasis by disrupting the blood-brain barrier .
-
In gliomas, DCUN1D1-positive tumor cells exhibit enhanced parenchymal invasion .
Cullin Specificity
-
Inhibitors like DI-591 (targeting DCN1-UBC12) selectively block cullin 3 neddylation, upregulating NRF2—a substrate of cullin 3 CRL .
-
Unlike pan-neddylation inhibitors (e.g., MLN4924), DCUN1D1 modulation allows selective CRL targeting .
Mechanistic Insights
-
DCUN1D1 binds cullins via a conserved surface and UBC12 through overlapping E1/E2 interaction sites .
-
Structural studies reveal a hydrophobic pocket in DCUN1D1 critical for UBC12 binding, enabling inhibitor design (e.g., DI-591 with K<sub>i</sub> = 10–12 nM) .
Tissue-Specific Roles
Product Specs
Target Background
Q&A
Basic Research Questions
How to validate DCN-1 antibody specificity in experimental systems?
-
Methodological steps:
-
Perform Western blotting with positive/negative control lysates (e.g., DCN-1 knockout cell lines) to confirm target band absence/presence .
-
Use siRNA-mediated knockdown followed by immunofluorescence to verify reduced signal intensity .
-
Validate cross-reactivity using protein arrays or immunoprecipitation-MS to identify off-target interactions .
-
What experimental controls are critical for DCN-1 antibody-based assays?
How to select DCN-1 antibodies for dual-labeling experiments?
-
Prioritize antibodies raised in different host species (e.g., rabbit anti-DCN-1 paired with mouse anti-target).
-
Validate using single-antibody staining followed by spectral unmixing to exclude bleed-through artifacts .
Advanced Research Questions
How to resolve contradictory DCN-1 localization data across studies?
-
Stepwise approach:
-
Compare fixation/permeabilization protocols (e.g., methanol vs. paraformaldehyde) affecting epitope accessibility .
-
Analyze antibody clonality: Monoclonals may recognize linear epitopes disrupted by denaturation; polyclonals detect conformational epitopes .
-
Quantify using orthogonal methods (e.g., mRNA/protein correlation in single-cell RNA-seq datasets) .
-
What computational tools predict DCN-1 antibody-antigen binding interfaces?
How to design DCN-1 antibodies with isoform-specific binding?
-
Strategy:
-
Identify unique epitopes in target isoform via alignment (e.g., DCN-1α vs. DCN-1β C-terminal divergence).
-
Generate phage library biased toward divergent regions using structure-guided mutagenesis .
-
Screen under competitive conditions with off-isoform proteins to counterselect cross-reactive clones .
-
Methodological Best Practices
-
Batch variability mitigation:
-
Quantitative reporting:
